Acrux (ASX:ACR) Gains FDA Pathway Clarity as Commercial Receipts Increase

Aditi Sarkar

14 August 2026 12:27 PM AEST

Acrux (ASX:ACR) Gains FDA Pathway Clarity as Commercial Receipts Increase

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Healthcare

Highlights

Acrux Limited (ASX:ACR) received FDA feedback outlining the pathway towards a Phase III program for its female testosterone product.
FY26 customer receipts increased to A$5.002 million, compared with A$0.521 million in the prior year.
The company continues discussions with potential pharmaceutical partners for co-development of its female testosterone program.
Commercial products and licensing arrangements contributed to higher receipts during FY26.

Acrux Limited (ASX:ACR) has progressed its female testosterone development program while reporting higher customer receipts from its commercial portfolio. The company’s latest quarterly update provided further clarity on the regulatory pathway for its Hypoactive Sexual Desire Disorder (HSDD) treatment candidate and highlighted increased contributions from topical generics and licensing arrangements.

The company continues to balance development of higher-value proprietary programs with Revenue generation from existing commercial products.

What Happened?

On 31 July 2026, Acrux Limited (ASX:ACR) released its quarterly report, confirming that the United States Food and Drug Administration (FDA) had provided feedback on the pathway for a Phase III clinical trial program for its female testosterone product.

The product is being developed for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in women. Acrux stated that the FDA had reviewed areas including preclinical safety data, toxicology information and Manufacturing plans.

The company has completed Phase I and Phase II trials and is progressing discussions with pharmaceutical partners to support the Phase III program.

Alongside the regulatory update, Acrux reported higher cash receipts from its commercial portfolio.

Why It Matters

The female testosterone program represents a potential expansion opportunity for Acrux in women’s health. Currently, there is no FDA-approved testosterone product specifically designed for women in the United States for this indication.

The FDA feedback provides greater visibility around the requirements for advancing the program into Phase III development.

Acrux intends to progress the program through partnerships, which could reduce the financial burden associated with late-stage clinical development while providing access to additional resources.

The Numbers

Acrux reported FY26 customer receipts of A$5.002 million, compared with A$0.521 million in FY25, representing a 960% increase.

Customer receipts for the June quarter were A$1.780 million.

Full-year operating expenditure was A$6.876 million, and the company ended the period with A$1.705 million in cash.

Revenue contributions included commercial products and licensing arrangements. Acrux received an initial milestone payment of A$1.350 million from Gedeon Richter Plc under the Lenzetto Partnership in Australia.

Future Lenzetto milestone payments of up to A$4.05 million are linked to regulatory approval and sales targets and remain conditional.

Products marketed through US licensee Tru Pharma, including Nitroglycerin 0.4% ointment and Dapsone 7.5% gel, also contributed to customer receipts.

The Bigger Picture

Acrux’s Business has historically focused on transdermal drug-delivery technology, including systems used in products such as Evamist and Lenzetto.

In recent years, the company has developed a commercial portfolio of topical generics while continuing to advance proprietary pharmaceutical programs.

The increase in customer receipts indicates a greater contribution from commercial products, providing additional support while the company develops longer-term opportunities.

The female testosterone program remains a key development focus, with potential future value dependent on regulatory progress, partnership outcomes and clinical results.

The Bull Case

The positive case for Acrux Limited (ASX:ACR) is based on progress across both development and commercial activities.

The company has moved its female testosterone program towards a more defined regulatory pathway, reducing uncertainty around Phase III requirements.

A successful partnership agreement could provide additional funding support for clinical development while sharing execution responsibilities.

The commercial portfolio also provides an existing revenue base, with higher FY26 customer receipts reflecting contributions from licensing arrangements and generic products.

Risks Investors Should Understand

Acrux Limited (ASX:ACR)’s business faces risks including clinical trial outcomes, regulatory approval requirements, partnership uncertainty, funding needs and commercial execution.

FDA feedback on a Phase III pathway does not represent approval, and the clinical program still requires successful trial design, funding and execution.

The company has stated that it is seeking development partners, but no agreement has been announced.

Acrux’s cash position remains limited compared with operating expenditure, making continued reliance on licensing income, milestone payments and potential funding arrangements an important consideration.

Future milestone payments remain conditional on regulatory approvals and sales targets.

What Comes Next?

The next key milestones include potential partnership discussions for the female testosterone program, confirmation of the Phase III trial design and further commercial progress from existing products.

Investors will also monitor potential Lenzetto regulatory milestones in Australia and ongoing contributions from the company’s generic portfolio.

Additional licensing agreements or product developments could influence future revenue visibility.

Conclusion

Acrux Limited (ASX:ACR) has provided further clarity on its female testosterone program while reporting higher customer receipts from its commercial portfolio.

The FDA pathway update provides a clearer development framework, while increased receipts from licensing and generic products strengthen the company’s commercial base.

However, the female testosterone program still requires partnership support, successful Phase III development and regulatory approval. The company’s future progress will depend on converting regulatory milestones into commercial outcomes while maintaining financial flexibility.

FAQs

Q: What is Acrux Limited developing?

A:Acrux is developing a female testosterone product for Hypoactive Sexual Desire Disorder (HSDD) in women.

Q: What did the FDA provide to Acrux?

A:The FDA provided feedback on the pathway requirements for a Phase III clinical trial program.

Q: How much were Acrux’s FY26 customer receipts?

A:Acrux reported FY26 customer receipts of A$5.002 million.

Q: Does Acrux have a commercial product portfolio?

A:Yes, Acrux generates receipts from commercial products, licensing arrangements and generic pharmaceutical products.

Q: What are the key risks for Acrux?

A:Key risks include clinical trial outcomes, regulatory approval, partnership arrangements and funding requirements.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.